All Comparisons
Tirzepatide vs Sermorelin
Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.
Tirzepatide: ASermorelin: C
| Attribute | Tirzepatide | Sermorelin |
|---|---|---|
| Category | Metabolic / Dual GIP-GLP-1 Agonist | Growth Hormone Secretagogue |
| Evidence Rating | A — FDA Approved | C — Phase I–II Clinical Trials |
| Clinical Status | FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA) | Previously FDA-approved (Geref, discontinued); now used off-label via compounding |
| Mechanism | Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, increases satiety ... | Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. The released HGH increases protein synthesis, fat breakdown (lipolysis), and tissue repair across multip... |
| Half-Life | ~5 days (116 hours) | ~10–20 minutes |
| Bioavailability | ~80% SC | — |
| Molecular Weight | ~4813.5 g/mol | ~3357.9 g/mol |
| WADA Status | Not Prohibited | Prohibited |
| Research Half-Life | ~5 days (116 hours) | ~10–20 minutes |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | FDA-approved: Mounjaro (T2D, adults and children 10+) and Zepbound (obesity/overweight with comorbidities, severe OSA including new sleep apnea approval). Compounding fully prohibited for 503B facilities. Prescription only. | Previously FDA-approved (Geref) for pediatric GH deficiency; voluntarily discontinued by manufacturer for commercial reasons. FDA confirmed in 2013 it was not withdrawn for safety. Available via compounding pharmacies. WADA-banned. |
Research Material Specifications
Catalog specifications for the corresponding research materials, including batch documentation coverage.
| Specification | Tirzepatide | Sermorelin |
|---|---|---|
| Purity Standard | ≥98% | ≥98% |
| CAS Number | 2023788-19-2 | 86168-78-7 |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ | C₁₄₉H₂₄₆N₄₄O₄₂S |
| Available Formats | 10mg, 30mg | 5mg |
| Batch COAs Published | — | — |
| Stock Status | In stock | Out of stock |
Availability at Volta Peptides
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.